Tag Archives: IPAB

FDA Gets More Funding, IPAB Gets Less

After two years in budget limbo, Congress finally enacted federal spending legislation for fiscal year 2014 last week, just before the latest funding extension ran out. In this period of ever-tighter government outlays, the Food and Drug Administration did fairly well in gaining additional funds, along with user fee revenues that had been put on […]
Posted in FDA, healthcare, Legal, Regulatory, Safety | Also tagged , , , , , , , | Leave a comment

Questions About the 2013 Implementation of IPAB

by Tom Norton With the general election behind us, the anticipated avalanche of ObamaCare regulations has begun.  Last week, it was reported that more than 13,000 pages of rules and regulations have been issued by HHS since Nov. 6th.   A huge amount of activity, to be sure, but as stated, not surprising.  That’s because the […]
Posted in FDA, healthcare, Legal, Market Access, pricing, Regulatory | Also tagged , , , , , , | Leave a comment

Obamacare After Nov 6th: Trouble for Pharma?

by Tom Norton No doubt the November 6th election is going to be close, very close: close for the Presidency, close for the Senate, and possibly close for the House.  So close, in fact, it’s possible that no substantial political change will occur in Washington, as a result. That said, for the U.S. pharmaceutical industry […]
Posted in Events, FDA, leadership, Legal, Market Access, pricing, R&D, Regulatory | Also tagged , , , | 3 Comments

Fixing Innovation: Lilly's CEO Says Why, and How

Following his keynote address last week at the Financial Times US Healthcare and Life Sciences Conference in New York, Eli Lilly CEO John Lechleiter huddled into a corridor to speak with PharmExec about his agenda as incoming chairman of PhRMA, and how to fix innovation.
Posted in Europe, Events, FDA, Global, healthcare, IP, leadership, Legal, Market Access, Meetings, People, pricing, R&D, Regulatory, Safety, Strategy, Technology | Also tagged , , , , , , , , , , , , | 1 Comment

IPAB : An HCR Acronym You Need to Understand

Tom Norton throws some light on the much-vaunted Independent Payment Advisory Board. Working towards our top issue for the June edition of the HCR Monthly Review, I continue to be struck by the amount of macroeconomic data that will be driving the new HCR law. Indeed, most of the key performance measures in the 2010 […]
Posted in healthcare, Regulatory | Also tagged , , , , , | 2 Comments
  • Categories

  • Meta